# Biostar Pharmaceuticals

Source: https://onco.cc/companies/biostar-pharmaceuticals/  
OnCo record `biostar-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Biostar Pharmaceuticals in Chengdu developed utidelone, the epothilone chemotherapy approved in China in 2021 for advanced breast cancer.

## Summary

Biostar Pharmaceuticals is a Chengdu biotechnology company built around genetically engineered epothilones. Its lead product utidelone was approved by the NMPA in March 2021 with capecitabine for recurrent or metastatic breast cancer after anthracyclines and taxanes; an oral formulation and trials in other tumours followed.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Chengdu Biostar
- Tags: ctgov-sponsor; china
- HQ: Chengdu, China
- Type: biotech
- Website: https://www.biostar.com.cn

## Sources

- Official website: https://www.biostar.com.cn

## Connected records

- fronts: [Chemotherapy](https://onco.cc/fronts/chemotherapy/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Utidelone](https://onco.cc/drugs/utidelone/)
- trials: [A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases](https://onco.cc/trials/nct06764940/), [Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct05700084/), [Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases](https://onco.cc/trials/nct06683703/)

---
JSON: https://onco.cc/api/v1/entities/biostar-pharmaceuticals.json